𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: Role of golgi apparatus

✍ Scribed by Francesco Fabbri; Wainer Zoli; Silvia Carloni; Paola Ulivi; Chiara Arienti; Giovanni Brigliadori; Marco Montanari; Anna Tesei; Rosella Silvestrini; Dino Amadori

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
562 KB
Volume
226
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The efficacy of therapy for hormone‐refractory prostate cancer (HRPC) is still unsatisfactory and new agents and therapeutic modalities are needed. The aims of the present work were to examine the in vitro activity and mechanisms of action of doxorubicin (DX), pegylated liposomal DX (PLDX), and non‐pegylated liposomal DX (NPLDX) in DU145 and taxane‐resistant DU145‐R HRPC cell lines. Drug activity and incorporation, apoptosis, and expression of cell death‐related markers were evaluated by SRB test, cytofluorimetric assays, and Western blot, respectively. Among the different DX formulations, NPLDX showed the highest cytotoxic activity in both cell lines, with more than 50% of apoptotic cells at only 1/10 of the plasma peak concentration after 72 h exposure. Anthracyclines, in particular NPLDX, were highly concentrated in the Golgi apparatus. Moreover, a significant increase was observed in the expression of CD95 receptor, GD3 ganglioside and, caspase‐2 and ‐8 active forms in both cell lines followed by caspase‐3 activation and mitochondrial membrane depolarization. The Golgi apparatus, probably acting as a stress sensor, intensified the conventional apoptotic mechanism induced by anthracyclines. Our data support the hypothesis that organelle‐dependent initiation of cell death other than that induced by mitochondria and nucleus is a research area worthy of pursuing and suggest that the Golgi apparatus could be an ideal target for anti‐cancer therapy. Of note, the activity of NLPDX in taxane‐resistant DU145‐R cells warrants further evaluation as second‐line treatment of advanced HRPC after taxane failure. J. Cell. Physiol. 226: 3035–3042, 2011. © 2011 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Activity of second-line chemotherapy in
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
✍ Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views

## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi

Voltage-gated K+ channel activity in hum
Voltage-gated K+ channel activity in human prostate cancer cell lines of markedly different metastatic potential: Distinguishing characteristics of PC-3 and LNCaP cells
✍ Marc E. Laniado; Scott P. Fraser; Mustafa B.A. Djamgoz 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

## BACKGROUND. Although ion channels are known to contribute to a variety of basic cellular behaviors involved in the metastatic cascade, their role in metastasis per se has only recently been questioned. The hypothesis tested was whether K channels were different between strongly metastatic PC-3